Document:

EXHIBIT 10.1

                    [LOGO OF SYNOVICS PHARMACEUTICALS, INC.]

                                                                   April 3, 2008

Svizera Holdings BV
Antennestraat 43, Post Box 60300,1320 AY
Almere, The Netherlands
Attention:        Mr. Vinay Sapte

Gentlemen:

         Reference is made to the following:

         i.    Subscription  Letter  (the  "SUBSCRIPTION"),  executed by you, to
               Kirk,  relating to the Convertible  Promissory Notes due June 30,
               2008 of Kirk (the  "NOTES")  and  shares of Series B  Convertible
               Preferred  Stock,  par  value  $0.001  per share  (the  "SERIES B
               SHARES"), of Synovics Pharmaceuticals, Inc., a Nevada corporation
               and  the  holder  of  all  of  the  equity   interests   in  Kirk
               ("SYNOVICS"), issued pursuant hereto and pursuant to the Notes;

         ii.   Collateral Agent Agreement,  dated April 3, 2008 (the "COLLATERAL
               AGENT  AGREEMENT"),  among Axiom  Capital  Management,  Inc.,  as
               collateral agent, and the Holders; and

         iii.  Letter, dated April 3, 2008 (the "SIDE LETTER"), from Synovics to
               the Holders (the "HOLDERS") of Notes.

Each of Synovics and Kirk, jointly and severally, make the following proposal to
Svizera Holdings BV, a wholly-owned  subsidiary of Maneesh  Pharmaceuticals Pvt.
Ltd. ("MANEESH"):

1. DEFINITIONS.  All capitalized terms used, but not otherwise  defined,  herein
shall  have  the  respective   definitions   assigned   thereto  in  the  Notes.
Notwithstanding  the  foregoing,  the  definition  of "Side Letter" in the Notes
shall be deemed to include this letter in the case of the addressee hereof.

2. MANEESH INVESTMENT.

<PAGE>

         (a)  Maneesh has  indicated  interest  in  participating  in the Bridge
Offering  as  well as the  Qualified  Equity  Financing.  The  Qualified  Equity
Financing and the conditions to the closing thereof are subject to, and shall be
set forth in, the definitive  documentation relating to the Qualified Financing.
The currently contemplated terms of the Qualified Equity Financing are set forth
in Exhibit C to the Notes.  The proceeds of the  participation of Maneesh in the
Bridge  Offering shall be utilized to pay the amounts  payable on March 31, 2008
to BOI and the balance will be used by Kirk for working capital purposes, except
(i) to the extent previously  discussed with Maneesh or (ii) as approved by John
Copanos and Harry Singh.

         (b) Synovics and Kirk  propose that Maneesh  participate  in the Bridge
Offering with an investment of  US$1,000,000  and  participate  in the Qualified
Equity Financing with an investment  US$5,000,000 to US$6,000,000 (including the
US$1,000,000  provided  in the  Bridge  Offering  and  "rolled  over"  into  the
Qualified  Equity  Financing).  Based upon its  discussions  with its investment
bankers,  Synovics  anticipates  that the Qualified  Equity Financing will close
within six weeks following the date hereof. Unlike other investors in the Bridge
Offering,  Maneesh  shall be entitled to the  following  additional  right:  if,
within 100 days  following the closing of the Bridge  Offering,  the  conditions
described  below are not satisfied,  the Bridge Notes acquired by Maneesh in the
Bridge Offering shall become due with interest.

         (c) Maneesh will be entitled to  registration  rights on the same basis
as other investors in the Bridge  Offering and Qualified  Equity  Financing.  As
Maneesh will likely be deemed to be an  "AFFILIATE"  of Synovics  following  the
Bridge  Offering,  Maneesh  will be subject to  restrictions  on its  ability to
resell as provided by  applicable  law.  Counsel to  Synovics  is  available  to
explain these restrictions at your convenience.

3. ADDITIONAL  COVENANTS.  As an additional inducement to Maneesh to enter into,
and perform,  the  Subscription  upon the terms set forth  herein,  Synovics and
Kirk, jointly and severally agree as follows:

 Financial          All bridge notes currently outstanding and held or placed by
 Instrument         affiliates  of  2133820  Ontario  Inc.,  Maneesh  and  Axiom
 Equality           Capital/Indigo  and the notes issued in the Bridge  Offering
                    shall be under the same terms and  conditions  and all funds
                    will be  treated  equally,  e.g.  PARI  PASSU,  and shall be
                    exchanged for the  securities in the Bridge  Offering at the
                    initial  closing  thereof.  The Bridge  Offering  includes a
                    US$500,000 senior secured note component (which ranks senior
                    to the  remainder of the Bridge  Offering)  which may not be
                    acquired  by  any  of  the  following  or  their  respective
                    affiliates:  Harry Singh,  2133820 Ontario Inc., Greg Osborn
                    or Axiom.

 Board Structure    Upon release from escrow of Maneesh's investment in

<PAGE>

                    Synovics   pursuant  to  the  Qualified  Equity   Financing,
                    Synovics  agrees to  reorganize  its board of  directors  as
                    follows:

                    All existing Board members will resign, other than Ron Lane.
                    Immediately  thereafter,  the  Board  shall  designate  four
                    additional individuals  (referenced in items "b" through "e"
                    below) and shall consist of five  members.  Upon approval of
                    the new Board,  the Board will have the right to expand to 7
                    board  seats.  The Board will  initially be  constituted  as
                    follows   and  each  of  members  of  the  Board  (or  their
                    appointees,  as applicable) and their respective  affiliates
                    shall  enter  into a written  agreement  agree to vote their
                    securities in favor of the representatives of the others:

                    a. Ron Lane
                    b. 2133820 Ontario Inc. representative (Harry Singh)
                    c. Maneesh Representative
                    d. Maneesh Representative
                    e. Axiom Representative
                    f.* Maneesh Pharmaceuticals Representative
                    g.* Axiom Capital/Middlebury Securities Representative

                    *Preferably  CPA or a candidate whom is able to qualify as a
                    audit committee chairman as described under Sarbanes-Oxley.

                    Ron Lane shall Lane shall serve as Chairman of the Board for
                    six months commencing on the date of the last closing of the
                    Qualified  Equity  Financing  and shall be  responsible  for
                    regulatory and legal compliances and investor  relations.  A
                    new  chairman  may be  elected  by  the  new  Board,  at its
                    discretion, following such six month period.

                    At no time  may  any of  Harry  Singh,  Maneesh,  Axiom,  or
                    Middlebury   Securities,   together  with  their  respective
                    affiliates,  elect in  excess of 49% of the  members  of the
                    Board unless their  ownership  exceed 50% of the outstanding
                    voting securities of Synovics.

 Due Diligence      a. Maneesh will conduct a due diligence investigation of the
                    financial,  legal and regulatory status of Kirk and Synovics
                    in conjunction with Axiom Capital.

                    b. Maneesh will deposit the proceeds of the Qualified Equity
                    Financing to be provided  thereby in an escrow

<PAGE>

                    account  with all other  proceeds  of the  Qualified  Equity
                    Financing.  The  funds  in  such  escrow  account  shall  be
                    released upon the  satisfaction  of the terms and conditions
                    of  the  "Qualified  Equity  Financing"  set  forth  in  the
                    definitive  documentation  relating thereto. These terms and
                    conditions  include  the  satisfactory   conclusion  of  due
                    diligence,  a minimum of  US$15,000,000 of gross proceeds in
                    the  Qualified  Financing  (including  100% of the principal
                    amount of the Notes and the  principal  amount of 2006 Notes
                    that  opt to  convert  into  Series  C  Preferred  Stock  in
                    connection with the Qualified Equity Financing),  and a "Use
                    of Proceeds"  reasonably  agreeable to Synovics,  Axiom, and
                    Maneesh.

                    c. Maneesh reserves the right to withdraw from the financing
                    if not  satisfied  with the  outcome of due  diligence,  and
                    Synovics will not make claims and shall promptly  return the
                    portion of the proceeds in such escrow  account  provided by
                    Maneesh.

 Support Services   a.  Hiring of a focused  IR firm,  approved  by the board at
                    close.

                    b.  Hiring  of  Conversion  Agents,  Inc.  for  purposes  of
                    clearing shares on behalf of all investors.

 Consulting Fees    a. Harry Singh to receive  2,000,000  shares of common stock
                    vested over 24 months: 1/3 at close of Qualified, 1/3 at 1st
                    anniversary, and 1/3 at the second anniversary

                    b. Ron Lane to  receive  1,000,000  shares of common  stock,
                    vested over 24 months: 1/3 at close of Qualified, 1/3 at 1st
                    anniversary, and 1/3 at the second anniversary

                    c.  Repricing of Greg  Osborn's  existing  Indigo  placement
                    warrants to current  strike  price (not  increase in amount)
                    subject  to the same  being  done  with  Maneesh's  existing
                    warrants from its prior investment.

                    e.  Issuance of 4,000,000  shares of common stock to Maneesh
                    for  guaranteeing  the  current  Bank Of  India  loan in the
                    principal amount of approximately  US$6,950,000,  subject to
                    increase  pursuant  to  clause  "f"  below,  subject  to the
                    execution and delivery of a definitive guaranty satisfactory
                    to  Maneesh.  Maneesh  shall have the  exclusive  ability to
                    negotiate  to serve as  guarantor  of the Bank of India loan
                    for seven  days  commencing  on the date  hereof.

<PAGE>

                    (It  being   understood  that  the  ability  of  Maneesh  to
                    participate in the Qualified  Equity  Financing shall not be
                    contingent upon the execution of any such guarantee.)

                    f.  Issuance of an  additional  3,000,000  common  shares in
                    stock to Maneesh for having the Bank of India  increase  the
                    available   principal  amount  of  the  credit  facility  to
                    US$10,000,000,  subject to the  execution  and  delivery  of
                    documentation   effecting  and  guaranteeing  such  increase
                    satisfactory to Maneesh and Synovics.

                    g. 250,000 warrants to be issued to each non-executive Board
                    member.  These  warrants will be priced at exercise price of
                    the warrants issued in connection with the Kirk Bridge.

                    h. Up to 2,000,000  shares to be utilized in  non-affiliated
                    investor  negotiations  (e.g., none of the parties described
                    in this agreement).

 Other Conditions   a.  Waiver  or   settlement  of  all penalties   for   prior
 To Closing of      non-compliances.
 the Qualified
 Equity Financing   b.  The  resale  of  Maneesh's   current   shares  shall  be
                    registered under the Securities Act of 1933, as amended,  on
                    a basis consistent with the  registration  rights granted in
                    connection  with the Qualified  Financing.  Maneesh will not
                    pursue  any   penalties   for   non-registration   or  prior
                    non-compliances.

                    c. Synovics shall resolve all claims  relating to the Indigo
                    financing conducted during 2005.

                    d.  Synovics  shall  agree that  Copanos to be paid  between
                    $1,250,000  and  $1,500,000  of his note  principal,  and at
                    least  US$500,000  principal amount of the remainder of such
                    note shall convert into securities  offered in the Qualified
                    Financing. Copanos shall enter into a non-compete with Kirk,

                    e. CB Distributors to be paid off any remaining principal or
                    interest.

                    f. Salary cap for Ron Lane of US$400,000,  US$200,000  shall
                    be  payable  in cash and  US$200,000  accrued  in  shares of
                    common  stock  until  Synovics   achieves  positive  EBITDA,
                    determined in accordance with generally accepted

<PAGE>

                    accounting principles applied on a basis consistent with the
                    latest audited financial statements of Synovics.

                    g. Mandatory conversion of $100,000 of accrued salary by Ron
                    Lane into the securities offered in the Qualified Financing.

                    h. New CEO  identified  by final  closing  of the  Qualified
                    Financing.

                    i.  Delivery  of  US$1,000,000  to  Synovics  for the Bridge
                    Offering by Maneesh.  Maneesh  shall be offered the right to
                    participate   in   the   Qualified   Financing   for  up  to
                    US$6,000,000  (including the conversion of its investment in
                    the Bridge Offering).  Such  US$1,000,000  investment in the
                    Bridge  Offering  shall  be  wired  to the  existing  escrow
                    account  and  released  immediately  to the  Kirk  operating
                    account as outlined.

                    j. At the closing of the Qualified Equity Financing at which
                    the  aforementioned   $6,000,000  participation  of  Maneesh
                    (including the "roll over" of the  participation  of Maneesh
                    in the Bridge  Offering) is received by  Synovics,  Synovics
                    shall reimburse Maneesh for due diligence  expenses incurred
                    in connection with the Qualified Equity Financing,  provided
                    that such expenses may not exceed $10,000.

         If the  foregoing  is  acceptable,  please  execute  this letter  where
indicated below to indicate your agreement therewith.

                                     SYNOVICS PHARMACEUTICALS, INC.

                                     By: /S/ RONALD H. LANE
                                         ------------------
                                          Ronald H. Lane, Ph.D.
                                          Chairman of the Board of Directors and
                                              Chief Executive Officer

ACCEPTED AND AGREED TO AS OF
THE DATE FIRST ABOVE-WRITTEN:

SVIZERA HOLDINGS BV

By: /S/ VINAY SAPTE
    ---------------
     Name: Vinay Sapte
     Title:EXHIBIT 10.2

                    [LOGO OF SYNOVICS PHARMACEUTICALS, INC.]

                                                                  April 24, 2008

Svizera Holdings BV
Antennestraat 43, Post Box 60300,1320 AY
Almere, The Netherlands
Attention:    Mr. Vinay Sapte

Gentlemen:

         Reference is made to that certain agreement between Svizera Holdings BV
("Svizera") and Synovics Pharmaceuticals, Inc. ("Synovics") dated April 3, 2008
(the "Maneesh Side Letter").

         1. AMENDMENT TO MANEESH SIDE LETTER. The Maneesh Side Letter is hereby
amended by deleting the existing text of Section 3 thereof under the caption
"Board Structure" and replacing it with the following:

  "Board Structure  Upon release from escrow of Maneesh's investment
                    in Synovics pursuant to the Qualified Equity Financing,
                    Synovics agrees to reorganize its board of directors as
                    follows:

                    All existing Board members will resign, other than Ron Lane.
                    Immediately thereafter, the Board shall designate four
                    additional individuals (referenced in items "b" through "e"
                    below) and shall consist of five members. Upon approval of
                    the new Board, the Board will have the right to expand to 7
                    board seats. The Board will initially be constituted as
                    follows and each of members of the Board (or their
                    appointees, as applicable) and their respective affiliates
                    shall enter into a written agreement agree to vote their
                    securities in favor of the representatives of the others:

                    a. Ron Lane
                    b. 2133820 Ontario Inc. representative (Harry Singh)
                    c. Maneesh Representative
                    d. Maneesh Representative
                    e. Maneesh Representative (For successfully giving guarantee
                    to BOI replacing Guaranty by Nostrum and

<PAGE>

                    Nirmal Mulye before 28th April)
                    f.* Maneesh Pharmaceuticals Representative
                    g.* Axiom Capital/Middlebury Securities Representative

                    *Preferably CPA or a candidate whom is able to qualify as a
                    audit committee chairman as described under Sarbanes-Oxley.

                    Ron Lane shall serve as Chairman of the Board for six months
                    commencing on the date of the last closing of the Qualified
                    Equity Financing and shall be responsible for regulatory and
                    legal compliances and investor relations. A new chairman may
                    be elected by the new Board, at its discretion, following
                    such six month period.

                    At no time may any of Harry Singh, Maneesh, Axiom, or
                    Middlebury Securities, together with their respective
                    affiliates, elect in excess of 49% of the members of the
                    Board unless their ownership exceed 50% of the outstanding
                    voting securities of Synovics."

         2. EFFECT OF AMENDMENT. Except as expressly amended by Section 1
hereof, the Maneesh Side Letter shall remain in full force and effect and
unamended.

         If the foregoing is acceptable, please execute this letter where
indicated below to indicate your agreement therewith. This letter may be
executed in two or more counterparts each of which shall be an original and all
of which together shall constitute one and the same instrument.

                                 SYNOVICS PHARMACEUTICALS, INC.

                                 By: /S/ RONALD H. LANE
                                     ----------------------------
                                      Ronald H. Lane, Ph.D.
                                      Chairman of the Board of Directors and
                                          Chief Executive Officer

ACCEPTED AND AGREED TO AS OF
THE DATE FIRST ABOVE-WRITTEN:

SVIZERA HOLDINGS BV

By: /S/ VINAY SAPTE
    ---------------
     Name: Vinay Sapte
     Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]